Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

ETHSX vs. QAAGZX: which is better?

Bottom line

ETHSX vs QAAGZX: the short answer

ETHSX (Eaton Vance Worldwide Health Sciences Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 64% by weight.

But QAAGZX is far broader, holding 277 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.

QAAGZX is cheaper at 0.86% vs 1.18% — a difference of $32 a year per $10,000 invested.

Over five years, ETHSX returned +5.3% a year vs +4.1% for QAAGZX (reporting dates differ).

ETHSX has a front-end sales load of up to 5.25%; the other does not.

Updated Nov 19, 2026

ETHSX vs QAAGZX side by side

ETHSXQAAGZX
TypeMutual fundETF
Fund familyMorgan StanleyT. Rowe Price
CategoryHealth Care SectorHealth Care Sector
Expense ratio1.18%0.86%
Annual cost per $10k$118$86
10-yr cost on $10k (prospectus)$1,911$1,061
Max front load5.25%None
12b-1 fee0.25%0%
1-yr return−1.9%+18.1%
5-yr return (annualized)+5.3%+4.1%
10-yr return (annualized)+6.4%+9.0%
Best quarter+14.2%+23.4%
Worst quarter−12.1%−15.8%
Net assets (fund)$757.9M$751.7M
Number of holdings42277
Portfolio turnover3%65%
Returns as ofDec 31, 2024Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearETHSXQAAGZXDifference
2024+3.5%+1.7%+1.9%
2023+5.7%+3.0%+2.7%
2022−9.4%−12.5%+3.0%
2021+22.1%+13.1%+9.0%
2020+13.0%+29.6%−16.6%
2019+26.0%+29.0%−3.0%
2018+6.0%+1.1%+4.9%
2017+16.2%+27.6%−11.3%
2016−14.9%−10.5%−4.4%

Source: Fund prospectus bar charts

Holdings overlap

12 of ETHSX's top 25 holdings also appear in QAAGZX's top 25.

Shared top holdings
HoldingETHSXQAAGZX
Eli Lilly & Co12.47%14.06%
AbbVie Inc6.46%5.12%
Johnson & Johnson6.45%6.64%
UnitedHealth Group Inc5.49%5.88%
Merck & Co Inc5.08%4.00%
Bristol-Myers Squibb Co4.25%2.12%
Vertex Pharmaceuticals Inc3.38%2.26%
Gilead Sciences Inc3.34%2.79%
Thermo Fisher Scientific Inc2.79%2.53%
Intuitive Surgical Inc2.72%1.89%
Stryker Corp2.21%1.78%
Abbott Laboratories1.65%1.91%

Source: SEC Form N-PORT

ETHSX top 10

  1. Eli Lilly & Co — 12.47%
  2. AbbVie Inc — 6.46%
  3. Johnson & Johnson — 6.45%
  4. AstraZeneca PLC — 6.24%
  5. UnitedHealth Group Inc — 5.49%
  6. Roche Holding AG — 5.44%
  7. Merck & Co Inc — 5.08%
  8. Bristol-Myers Squibb Co — 4.25%
  9. Vertex Pharmaceuticals Inc — 3.38%
  10. Gilead Sciences Inc — 3.34%

QAAGZX top 10

  1. Eli Lilly & Co — 14.06%
  2. Johnson & Johnson — 6.64%
  3. Unitedhealth Group Inc — 5.88%
  4. Abbvie Inc — 5.12%
  5. Merck & Co. Inc. — 4.00%
  6. Gilead Sciences Inc — 2.79%
  7. Thermo Fisher Scientific Inc — 2.53%
  8. Vertex Pharmaceuticals Inc — 2.26%
  9. Bristol-myers Squibb Co — 2.12%
  10. Abbott Laboratories — 1.91%

FAQ

What is the difference between ETHSX and QAAGZX?
ETHSX (Eaton Vance Worldwide Health Sciences Fund) and QAAGZX (T. Rowe Price Health Sciences Portfolio) share a meaningful slice of their top holdings — about 64% by weight. But QAAGZX is far broader, holding 277 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
Which is cheaper, ETHSX or QAAGZX?
QAAGZX has the lower expense ratio (0.86%).
Should I own both ETHSX and QAAGZX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.